Volume 5, 2021



Šaćira Mandal

Pages: 132–135

DOI: 10.21175/RadProc.2021.25

Leptin is a hormone secreted from adipose tissue (AT) that plays important role in metabolism of carbohydrate, proteins, and lipids. Also, leptin and its receptors are key regulators of body weight and energy metabolism. Previous studies, demonstrated that plasma leptin improved glucose and lipid metabolisms independently of the food intake reduction by decreasing in blood glucose and insulin levels as well as triacylglycerol stores in the body. Objective of this study was to evaluate the relationship between plasma leptin concentration and lipid profile in healthy and diabetic individuals. Twenty-six participants were recruited in the study, 13 newly diagnosed and non-treated Type 2 diabetes (T2D) patients and 13 healthy controls. Metabolic variables including glucose, glycated hemoglobin, lipids: total cholesterol, triacylglycerol, high density lipoprotein, low density lipoprotein and very low-density lipoprotein, and hormone concentrations leptin and insulin were measured. Plasma leptin concentration was an increased significantly (p<0.001) in diabetic patients compared to controls. Values of other biochemical characteristics were significant different between cases and controls (p<0.001). A significant association was demonstrated between leptin with BMI levels in participants (p<0.05) but not between leptin and lipid levels (p>0.05). Also, strong negative associations were observed between leptin and glucose levels among controls (p<0.009) as well a positive association leptin with HOMA-IS in diabetics (p<0.05). These results suggest that plasma leptin concentrations were affected by the increased levels of glucose, insulin and lipid profile in Bosnian study population. Therefore, leptin can be used as a biomarker of glucose and lipid control in newly diagnosed diabetic patients.
  1. American Diabetes Association, “Obesity Management for the Treatment of Type 2 Diabetes”, Diabetes Care, vol. 39, suppl. 1, pp. S47–S51, Jan. 2016.
    DOI: https://doi.org/10.2337/dc16-S009
  2. N. Katsiki, D.P. Mikhailidis, M. Banach, “Leptin, cardiovascular diseases and type 2 diabetes mellitus,” Acta Pharmacol. Sin., vol. 39, pp. 1176–1188, Jun. 2018.
    DOI: https://doi.org/10.1038/aps.2018.40
  3. A. Sarı, M.B. Sadeq, “The relationship the leptin hormone, obesity and diabetes,” Physical Sciences, vol. 15, no. 2, pp. 40–48, Apr. 2020.
    Retrieved from: https://dergipark.org.tr/en/pub/nwsaphysic/issue/53888/701533
    Retrieved on: Sep. 15, 2021
  4. T.H. Meek, G.J. Morton, “The role of leptin in diabetes: metabolic effects,” Diabetologia, vol. 59, no. 5, pp. 928–932, May. 2016.
    DOI: https://doi.org/10.1007/s00125-016-3898-3
  5. J. Seufert, “Leptin effects on pancreatic beta-cell gene expression and function,” Diabetes, vol. 53, suppl. 1, pp. S152–S158, Feb. 2004.
    DOI: https://doi.org/10.2337/diabetes.53.2007.S152
  6. T. Shiuchi et al., “Induction of glucose uptake in skeletal muscle by central leptin is mediated by muscle β2-adrenergic receptor but not by AMPK,” Sci. Rep., vol. 7, no. 1, article no. 15141, Nov. 2017.
    DOI: https://doi.org/10.1038/s41598-017-15548-6
  7. A.M. D’souza, U.H. Neuman, M.M. Glavas, T.J. Kieffer, “The glucoregulatory actions of leptin,” Molecular Metabolism, vol. 6, no. 9, pp. 1052–1065, Sep. 2017.
    DOI: https://doi.org/10.1016/j.molmet.2017.04.011
  8. T.M. Moonishaa et al., “Evaluation of leptin as a marker of insulin resistance in type 2 diabetes mellitus,” Int. J. Appl. Basic Med. Res., vol. 7, no. 3, pp. 176–180, 2017.
    DOI: https://doi.org/10.4103%2Fijabmr.IJABMR_278_16
  9. L. Marroquí et al., “Role of leptin in the pancreatic β-cell: effects and signaling pathways,” J. Mol. Endocrinol., vol. 49, no. 1, pp. R9–R17, 2012.
    DOI: https://doi.org/10.1530/jme-12-0025
  10. M.A. Buyukbese et al., “Leptin levels in obese women with and without type 2 diabetes mellitus,” Mediators of Inflammation, vol. 13, no. 5/6, pp. 321–325, Oct./Nov. 2004.
    DOI: https://doi.org/10.1080/09629350400008828
  11. W.I. Sivitz et al., “Leptin and body fat in type 2 diabetes and monodrug therapy,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 4, pp. 1543–1553, Apr. 2003.
    DOI: https://doi.org/10.1210/jc.2002-021193
  12. Y. Minokoshi, C. Toda, S. Okamoto, “Regulatory role of leptin in glucose and lipid metabolism in skeletal muscle,” Indian J. Endocrinol. Metab., vol. 16, suppl. 3, pp. S562–S568, Dec. 2012.
    Retrieved from: https://pubmed.ncbi.nlm.nih.gov/23565491/
    Retrieved on: Sep. 15, 2021
  13. L. O'Rourke, S.J. Yeaman, P.R. Shepherd, “Insulin and leptin acutely regulate cholesterol ester metabolism in macrophages by novel signaling pathways,” Diabetes, vol. 50, no. 5, pp. 955–961, May 2001.
    DOI: https://doi.org/10.2337/diabetes.50.5.955
  14. American Diabetes Association, “Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021,” Diabetes Care 2021, vol. 44, suppl. 1, pp. S15–S33, 2021.
    DOI: https://doi.org/10.2337/dc21-S002
  15. D.R. Matthews et al., “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, Jul. 1985.
    DOI: https://doi.org/10.1007/bf00280883
  16. S. Zhao, C.M. Kusminski, J.K. Elmquist, P.E. Scherer, “Leptin: less is more,” Diabetes, vol. 69, no. 5, pp. 823–829, May 2020.
    DOI: https://doi.org/10.2337/dbi19-0018
  17. W. Liu et al., “Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: A population-based study,” Medicine, vol. 99, no. 6, article no. e19052, Feb. 2020.
    DOI: https://doi.org/10.1097/MD.0000000000019052
  18. R. Farooq et al., “Type 2 diabetes and metabolic syndrome – adipokine levels and effect of drugs,” Gynecol. Endocrinol., vol. 33, no. 1, pp. 75–78, 2017.
    DOI: https://doi.org/10.1080/09513590.2016.1207165
  19. O. Gruzdeva, D. Borodkina, E. Uchasova, Y. Dyleva, O. Barbarash, “Leptin resistance: underlying mechanisms and diagnosis,” Diabetes Metab. Syndr. Obes., vol. 12, pp. 191–198, Jan. 2019.
    DOI: https://doi.org/10.2147/DMSO.S182406
  20. M. Obradovic et al., “Leptin and Obesity: Role and Clinical Implication,” Front. Endocrinol., vol. 12, article no. 585887, May 2021.
    DOI: https://doi.org/10.3389/fendo.2021.585887
  21. H. Zuo et al., “Association between serum leptin concentrations and insulin resistance: a population-based study from China,” PLoS ONE, vol. 8, no. 1, article no. e54615, Jan. 2013.
    DOI: https://doi.org/10.1371/journal.pone.0054615
  22. J. Huang, X. Peng, K. Dong, J. Tao, Y. Yang, “The association between insulin resistance, leptin, and resistin and diabetic nephropathy in type 2 diabetes mellitus patients with different body mass indexes,” Diabetes Metab. Syndr. Obes. Targ. Ther., vol. 14, pp. 2357–2365, May 2021.
    DOI: https://doi.org/10.2147/DMSO.S305054
  23. M. Mehrdad et al., “Association of FTO rs9939609 polymorphism with serum leptin, insulin, adiponectin, and lipid profile in overweight adults,” Adipocyte, vol. 9, no. 1, pp. 51–56, Dec. 2020.
    DOI: https://doi.org/10.1080/21623945.2020.1722550
  24. S. Mandal, “New molecular biomarkers in precise diagnosis and therapy of type 2 diabetes,” Health Technol., vol. 10, pp. 601–608, May 2020.
    DOI: https://doi.org/10.1007/s12553-019-00385-6
  25. C. Vavruch et al., “Using proximity extension proteomics assay to discover novel biomarkers associated with circulating leptin levels in patients with type 2 diabetes,” Sci. Rep., vol. 10, no. 1, article no. 13097, Aug. 2020.
    DOI: https://doi.org/10.1038/s41598-020-69473-2
Šaćira Mandal, "Determination of the plasma concentration of the protein product of the ob gene and lipid profile in bosnian type 2 diabetic individuals ",RAD Conf. Proc, vol. 5, 2021, pp. 132–135, http://doi.org/10.21175/RadProc.2021.25